Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T14:55:43.281Z.
Calculation as of: 2026-10-06T14:55:43.281Z.
Quote observation: 2026-10-06T14:55:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 397c5a59cd83d044dab6d82224f034cfcc72b23d5b6e8de026e21d37d80d55f6
PEG RATIO
N/A
Alector, Inc.
Market Cap
$211.50M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Alector, Inc. (ALEC) | $211.50M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $211.96M | N/A |
| Compugen Ltd. (CGEN)vs › | $214.16M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $220.33M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $203.43M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $223.78M | N/A |
| Biodesix, Inc. (BDSX)vs › | $225.53M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $230.42M | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $192.33M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
